September 16–17, Palau Macaya, Barcelona
HYBRIDGE
Shaping the future of pharmaceutical innovation.
Organized by:
Partnered by
Why this conference
Innovation based on known molecules is becoming increasingly strategic, yet the pathway remains highly complex. Whether described as Value-Added Medicines, Hybrid Medicines, 505(b)(2) products, or patient-centered innovation, success requires the alignment of regulatory requirements, clinical evidence, IP strategy, market access, and product differentiation from the earliest stages of development. In addition, significant differences exist not only between Europe and the US, but also across individual countries and healthcare systems, creating further challenges for global development strategies.
The HYBRIDGE Annual Conference is the first event dedicated to bringing together the different perspectives, expertise, and disciplines involved in the development of innovative medicines based on known molecules. Through specialized training, real-world experience, expert discussions, and practical insights, the conference aims to build bridges between regions, stakeholders, and approaches. This first edition will focus on hybrid medicines in Europe and 505(b)(2) pathways in the US.
Organized by ANNION Consulting, HYBRIDGE is built around three core principles:
- Industry expertise
- An end-to-end strategic perspective
- A collaborative network of professionals shaping the future of innovation based on known molecules
End-to-end scope
From ideation, IP and evidence generation to regulatory strategy, market access, BD and licensing.
Leading industry voices
Practical insight from professionals working directly on hybrid and 505(b)(2) programs.
Limited to 50 attendees
A focused format designed for meaningful discussion and high-value networking.
Two days to move from strategy to action
A practical setting to explore the future of value-added pharmaceutical innovation.
Why attend
Gain practical know-how in pharma innovation
Understand how known molecules can be developed with renewed clinical, technical and commercial value.
Learn from real industry experience
Hear from professionals who have worked across development, regulatory, BD and market access pathways.
Build regulatory clarity
Explore the requirements, opportunities and differences between European hybrid and US 505(b)(2) routes.
Connect through focused B2B networking
Connect with experts, innovators, strategic partners, and decision-makers across the global hybrid medicines and 505(b)(2) community.
Leave with an end-to-end framework
Take away practical perspectives to support smarter development and licensing decisions.
